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Abstract
It has been recently observed that statins might slow the progression of aortic stenosis or sclerosis.
Preliminary reports suggested a similar positive effect in reducing the degeneration of aortic valve
bioprostheses even though this hypothesis should be further proven and supported by new data.
In this review the present evidences of the possible effects of statins in this field are discussed.
Review
Nowadays many aortic valve prostheses are available in
clinical practice: mechanical, biological and human tissue
prostheses. None of the currently available prosthetic
valves, however, approach the human valve in terms of
hemodynamic function and/or freedom from complica-
tions. Mechanical prostheses have a longer durability and
provide a generally good hemodynamic function, but are
thrombogenic, requiring permanent anticoagulation with
related risks in terms of morbidity and mortality [1,2]. On
the contrary, bioprostheses have a low thrombogenicity
and do not require anticoagulation. On the other hand,
bioprosthetic valves have the propensity to undergo struc-
tural degeneration, limiting their durability and often
necessitating reoperation. For these reasons bioprosthetic
valves are usually used in old patients, while mechanical
ones are preferred in young people. In any case, it should
be recognized that the choice in the individual patient is
not simple.
Aortic valve replacement is one of the most frequently per-
formed cardiac surgery interventions in western countries
and the proportion of biological valves used in the aortic
position can be as high as 70% in patients over 70 years
[3,4]. Moreover, given the increased age at implantation
of the commonly referred patients, the proportion of bio-
logical prostheses is increasing. Thus, a medical therapy
able to reduce bioprosthetic valve structural degeneration
would have an important clinical and socio-economic
impact.
It has been recently observed that hydroxymethylglutaryl
coenzyme A reductase inhibitors might slow the progres-
sion of mild and moderate stenosis or sclerosis in native
aortic valves [5-7]. Several studies suggested that athero-
sclerosis and aortic valve stenosis could be considered
simply different manifestations of the same disease [8-
11]. In a cholesterol-fed rabbit model, hypercholestero-
lemia induced atherosclerotic-like lesions in the aortic
valve tissue, and atorvastatin reduced this phenomenon
[12]. Furthermore, a number of retrospective, non-rand-
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omized studies reported a possible effect of statins in
slowing progression of mild or moderate aortic stenosis in
human native valves [5-7]. Other studies [13,14] using
electron-beam computed tomography demonstrated a
decreased rate of aortic valve calcium accumulation in sta-
tin-treated patients. However, the real role of
hydroxymethylglutaryl coenzyme A reductase inhibitors
is not yet clarified. The correlation between cholesterol
levels and aortic stenosis progression is still controversial.
Some studies [5,13] found a significant correlation, while
other ones [6,7] showed lack of correlation with aortic ste-
nosis progression. Also the hypothesis that statin benefits
could be due to their pleiothropic and anti-inflammatory
properties has yet to be demonstrated.
In addition, the last two studies on this topic, published
this year, did not confirm the positive effect of
hydroxymethylglutaryl coenzyme A reductase inhibitors
on aortic stenosis progression (Table 1) [15,16]. Cowell et
al. [15] assessed aortic valve stenosis and calcification pro-
gression with Doppler echocardiography and computed
tomography, in a prospective double-blind-controlled
trial; patients were randomly assigned to receive either
atorvastatin or placebo. Their conclusion was that inten-
sive lipid-lowering therapy does not halt the progression
of calcific aortic stenosis or induce its regression. Our
group [16] demonstrated a positive effect of statins only
in the subgroup of patients with aortic valve sclerosis, sug-
gesting that these drugs could be effective only in the early
phase of disease.
The problem of early calcification of bioprosthetic valves
is well known. Indeed, at the time of commercial manu-
facturing [17], a treatment with the T6 (a detergent
sodium dodecyl sulphate to retard calcification [18]) is
usually performed to remove the lipids from the porcine
valve. Nevertheless, it cannot prevent subsequent lipid
insudation that may favor calcification. Anyway, with T6
mitigation, dystrophic calcification may be delayed until
other factors come into play. Lipid insudation and mono-
cyte infiltrates occur in the cuspidal tissue of porcine bio-
prostheses as seen in early atherosclerosis and can
precipitate structural valve deterioration in the long-term,
even in the absence of mineralization [19]. Bottio et al.
hypothezised that lipids could play a role in the structural
valve deterioration of bioprostheses. In their study they
observed, by electron microscopy, lipid insudations in
almost all the explanted biological valves [20].
Farivar and Cohn [21] have recently suggested that hyper-
cholesterolemia could be considered a risk factor for bio-
prosthetic valve calcification and explantation. They
performed a retrospective cohort study on 144 patients
who had bioprosthetic aortic or mitral valves removed. In
a subgroup of 66 patients they performed a case-control
analysis of the tissue valves explanted and compared them
with an age- and position-matched group of 66 patients
with similar duration of implantation. The mean serum
cholesterol level in the explanted valve group was signifi-
cantly higher (189 vs 163 mg/dL, p < .0001) than that of
the group whose valves did not require explantation. This
supports the potential role of hypercholesterolemia as a
risk factor for bioprosthetic valve calcification requiring
explantation. Similar results were found by Nollert et al.
[22]. In these two studies both aortic and mitral biopros-
theses were evaluated, but the role of statin treatment was
not addressed to.
David and Ivanov [23], analyzing two large databases
from Stanford University and Toronto General Hospital,
did not confirm a role of hyperlipidemia in predicting
freedom from reoperation after aortic valve replacement
Table 1: Aortic valve stenosis progression.
Author (year of 
publication) 
[reference]
N. patient 
(receiving 
statins)
Follow-up 
(months)
Mean age 
(years)
Prospective/
retrospective
Randomize
d/non 
randomized
CAD (%) A. Vel. max 
(m/sec)
Positive 
effect of 
statin
Aronow et al. (2001) 
[5]
180 (62) 33 82 ± 5 retrospective non-
randomized
NA NA Yes
Novaro et al. (2001) 
[6]
174 (57) 21 68 ± 12 retrospective non-
randomized
59 2,65 Yes
Bellamy et al. (2002) 
[7]
156 (38) 44 77 ± 12 retrospective non-
randomized
35 2,95 Yes
Rosenhek et al. (2004) 
[26]
211 (50) 24 70 ± 10 retrospective non-
randomized
27 3,96 Yes
Antonini-Canterin et 
al. (2005) [25]
242 (121) 48 67 ± 9 retrospective non-
randomized
46 2,45 No
Cowell et al. (2005) 
[15]
134 (65) 25 68 ± 11 prospective randomized 20 3,42 No
Authors of the studies with years follow-up, mean age, cardiovascular risk factors, peak aortic velocity and the presence of a positive effect of 
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with bioprosthetic valves. However, the authors could not
exclude the hypothesis that the probability of valve failure
in patients with risk factors for atherosclerosis was
reduced because most of them were actually taking stat-
ins.
Our group was the first one to observe a positive effect of
statins on reducing the progression of bioprosthetic aortic
valve degeneration [24,25]. In order to assess whether
statins play a role in slowing degeneration of biopros-
thetic aortic valves we have retrospectively selected from
our 15-years database (1988–2002) all the patients with
bioprosthetic aortic valves having at least 2 echocardio-
graphic examinations at least 6 months apart. There were
167 patients (97 men, mean age 71 ± 9 years at the first
examination), followed for 46 ± 38 months. During fol-
low-up, 22 patients (13%) were treated with statins, while
145 (87%) were not. There were no differences between
the two groups regarding age, gender, follow-up duration,
baseline peak aortic velocity, mean gradient, effective ori-
fice area, degree of aortic regurgitation, and left ventricular
ejection fraction. As expected, statin-treated patients had a
significantly higher prevalence of documented hypercho-
lesterolemia, proven coronary artery disease, and associ-
ated coronary artery bypass surgery (p < 0.001 for each).
There were no significant differences between the two
groups in prosthetic size, or prosthetic type (stented vs
stentless, or porcine vs pericardial valves). The annual rate
of increase in peak prosthetic velocity was lower in statin-
treated patients (0.038 ± 0.074 vs. 0.140 ± 0.228 m/sec/
year, p < 0.001). The annual rates of decrease in prosthetic
effective orifice area (0.031 ± 0.052 vs 0.100 ± 0.150 cm2/
year) and indexed effective orifice area (0.019 ± 0.031 vs
0.056 ± 0.086 cm2/m2/year) were also lower in statin-
treated patients (p < 0.001 for both) (Figure 1). Worsen-
ing of aortic regurgitation was found in 2/22 (9.1%) in the
statin group and in 48/145 (33.1%) of controls (p =
0.022). The existence of either a rate of increase in peak
velocity ≥ 0.3 m/s/year or worsening of aortic regurgita-
tion ≥ 1/3 degree was found in 2/22 (9.1%) of statin-
treated and in 63/145 (43.4%) of non-treated patients (p
= 0.002) (Odds ratio with statin treatment: 0.13; 95% CI,
0.03–0.58). The overall annual rate of progression in peak
prosthetic velocity was similar between porcine and peri-
cardial valves and between stented and stentless valves.
The only factor associated with a lower progression of bio-
prosthetic aortic valve failure was statin treatment. During
follow-up, there was no difference in major clinical event
occurrence between the two groups. No significant
adverse effects of statin treatment were recorded during
follow-up. Our study was the first one to provide evidence
that statin treatment is associated with significantly less
bioprosthetic aortic valve failure, opening a new field for
clinical research. It should be recognized, however, that
there are several limitations: given the small number of
patients with different types of bioprostheses on statins, a
meaningful subgroup analysis of the differences in out-
come between different types of biological prostheses was
not possible. Because of the retrospective nature of the
study and because of the inclusion period, complete infor-
mation regarding lipid profile was not available. There-
fore, we could not test for a relation between changes in
lipid profile and bioprosthetic aortic valve degeneration,
and so the mechanism of statin treatment benefit in this
setting remains speculative.
Rosenhek et al. [26], in a preliminary report, did not con-
firm the positive effect of hydroxymethylglutaryl coen-
zyme A reductase inhibitors on aortic valve bioprostheses.
A possible explanation for a lack of effect of statin treat-
ment in this study is the rather short follow-up (28 ± 17
months), as it would be sound to expect a benefit of statin
treatment in this setting after a longer period. Another
explanation could be the use of only peak transprosthetic
velocity and lack of inclusion of aortic regurgitation as a
measure of hemodynamic deterioration of bioprosthetic
aortic valves in their study. In two studies, Skowasch et al.
have recently supported the hypothesis of the inflamma-
tory process affecting aortic valve bioprostheses and the
pleiotropic effects of statins in these patients. In one study
[27], they analyzed the endstage degenerative aortic valve
tissue from native valve of 57 consecutive patients, tissue
from aortic porcine degenerated bioprostheses of 24
patients and tissue from 5 non-stenosed native control
valves; the serum C-reactive protein levels were also meas-
ured preoperatively. They found C-reactive protein more
frequently in bioprostheses than in native valves. Also the
serum C-reactive protein levels increased in patients with
aortic valve bioprostheses showing a significant correla-
Peak Prosthetic Velocity and Prosthetic Indexed Effective  Orifice Area Figure 1
Peak Prosthetic Velocity and Prosthetic Indexed Effective 
Orifice Area. Comparison of Annual Rate of increase in Peak 
Prosthetic Velocity (m/s/yr) and annual rate of change in 
Prosthetic Indexed Effective Orifice Area (EOA) (cm2/m2/yr) 
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tion with the valvular inflammatory process. Valvular C-
reactive protein expression and serum C-reactive protein
levels were found to be lower in the group of patients with
a statin treatment than in the group without it suggesting
possible pleiotropic and/or anti-inflammatory properties
of these molecules. In another study [28], the same
authors analyzed aortic valves from patients with non-
rheumatic aortic valve stenosis and with degenerative aor-
tic valve bioprostheses searching for the presence of
endothelial progenitor cells and leukocyte subtype-spe-
cific markers. These cells were detected in a large series of
degenerative aortic valves, more frequently in bioprosthe-
ses than in native cusps. These findings suggest not only a
unifying pathogenic mechanism that underlies both types
of valvular degeneration, but also an even more important
role of primarily extravalvular cells in the case of prosthe-
sis degeneration. In this work on high-grade aortic steno-
sis, a significant relationship between endothelial
progenitor cell markers and statins, aspirin or ACE-inhib-
itors was not found.
Aortic valve prostheses most often behave hemodynami-
cally like a mildly stenotic native valve and the pattern of
flow through the valve is similar. This mechanistic simi-
larity of the hydrodynamic patterns could be another
explanation for a similar benefit of statins treatment in
both native and bioprosthetic aortic valves. On the other
hand, statins exhibit pleiotropic effects over and above
lipid lowering, including anti-inflammatory effects [29].
They retard extra-osseous calcifications, as for coronary
vessels [30], and decrease native aortic valve calcium accu-
mulation [13,14]. Of note, doses used in statin-treated
patients in our study were relatively low compared to cur-
rently used dosages. Because of the submaximal doses the
actual effect of statins might have been underestimated. It
is also noteworthy that statin-treated patients had a
reduced progression of bioprosthetic degeneration
despite a higher number of risk factors.
Wu et al. [31] recently evaluated the effect of statins on
aortic valve myofibroblasts and osteoblast calcification in
vitro. Interestingly, statins inhibited calcification in aortic
valve myoblasts but paradoxically they stimulated bone
cell calcification in valve osteoblasts. At implantation,
bioprosthetic aortic valves represent "de novo" structures,
not yet affected by degenerative calcific process. Theoreti-
cally, statins could be more effective in this subgroup of
patients with bioprotheses as compared to the general
aortic native valve population, where the degenerative
process has already started and osteoblasts are likely to be
activated by statins.
Martinez-Gonzalez et al. [32] showed that human and
porcine smooth muscle cells share similar proliferation
dependence on the mevalonate pathway, inhibited by
statins treatment. They concluded that the porcine model
closely resembles the human model and it may be suita-
ble for testing new treatment strategies in vivo. More
recently, the same authors showed a positive effect of sta-
tin treatment on vessel wall expression of a protein
involved in atherosclerotic lesion progression in a hyper-
cholesterolemic porcine model [33]. This could explain in
part a similar positive effect of statins in human and por-
cine valves.
In conclusion, treatment with statins could be associated
with significantly less degeneration of bioprosthetic aortic
valves, but a definitive proof is still awaited. The data from
Cowell's study support the hypothesis that intensive lipid-
lowering therapy doesn't slow the progression of the aor-
tic stenosis of the native valve; but the same author rein-
force the need for a long-term and large-scale trial because
these were the limits of his investigations. The ASSIST
study (Asymptomatic aortic Sclerosis/Stenosis: Influence
of STatins), an ongoing study of the "Società Italiana di
Ecografia Cardiovascolare", is aiming to create a large,
prospective, observational investigation, involving many
Echocardiograpic laboratories and thousands of patients,
in order to give more definite answers from the real clini-
cal world to this unsolved question. A substudy of the
ASSIST study on aortic biological prostheses is also
planned, in order to prospectively assess, in a large
number of patients, the potential role of this pharmaco-
logic treatment in reducing the rate of prostheses degener-
ation.
Conclusion
The potential role of statin treatment in reducing the rate
of aortic biological prostheses degeneration has not been
clarified yet. Nowadays studies are discordant but a large,
prospective, observational investigation is lacking. On
going studies could answer some of the unsolved ques-
tions.
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